Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 185 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Postmenopausal Osteoporosis Clear all
Completed Phase 2 Interventional

PTHrP and Osteoporosis

NCT00021827
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid hormone-related protein or ''PTHrP''
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years to 75 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hesperidin and Bone Health in Postmenopausal Women

NCT01881204
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Hesperidin and Calcilock, Hesperidin, Control
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 2Phase 3 Interventional

To Study the Efficacy and Safety of Doxercalciferol on Spinal and Femoral Density in Postmenopausal Osteopenic Women in a Long Term 2 Year Study

NCT07660536
View directory record Official record
Conditions
Osteoporosis (Senile)
Interventions
doxercalciferol capsules, Hectorol®, Matched Placebo (Capsules)
Drug
Lead sponsor
Creighton University
Other
Eligibility
60 Years to 78 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 1994
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Prunes Preventing Bone Loss in Perimenopause

NCT07120997
View directory record Official record
Conditions
Perimenopausal Bone Loss
Interventions
Prunes, Calcium supplement, Vitamin D Supplement
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
44 Years to 55 Years · Female only
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women

NCT01250145
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
LY333334, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Female only
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Daytona Beach, Florida • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

NCT04729621
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
TVB-009, Prolia®
Combination Product
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 4 Interventional

Long Term Effects of Raloxifene Treatment on Bone Quality

NCT00532428
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
Raloxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Indianapolis, Indiana • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis

NCT00005005
View directory record Official record
Conditions
Osteoporosis
Interventions
PTH, Alendronate
Drug
Lead sponsor
Dennis Black
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
4
States / cities
Bangor, Maine • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 4 Interventional Results available

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women

NCT00504166
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
alendronate sodium, placebo comparator
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Not applicable Interventional

Optimizing Body Composition & Health After Breast Cancer

NCT00659906
View directory record Official record
Conditions
Breast Neoplasm, Osteoporosis, Postmenopausal
Interventions
Resistance Exercise, Flexibility Training
Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 17, 2026, 6:24 PM EDT
Completed No phase listed Observational

Circulating miRNA in Primary Hyperparathyroidism

NCT03931109
View directory record Official record
Conditions
Primary Hyperparathyroidism, Osteoporosis, Postmenopausal
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

NCT01674621
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg), Abaloparatide Injection (80 mcg), Abaloparatide Placebo
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
Up to 85 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Lakewood, Colorado • Atlanta, Georgia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)

NCT00145327
View directory record Official record
Conditions
Osteoporosis
Interventions
Zoledronic Acid, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
68 Years to 90 Years · Female only
Enrollment
2,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
30
States / cities
Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density

NCT00114270
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
letrozole, zoledronic acid
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 17, 2026, 6:24 PM EDT
Completed No phase listed Observational Results available

Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

NCT04974723
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Abaloparatide, Teriparatide
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years and older · Female only
Enrollment
22,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 4 Interventional Results available

Preventing Osteoporosis Using Denosumab

NCT02753283
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures
Interventions
denosumab, Placebo, Calcium and Vitamin D
Drug · Dietary Supplement
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 3 Interventional

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

NCT00383422
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Arzoxifene, Raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Gainesville, Georgia • Urbandale, Iowa • Billings, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration

NCT04026256
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Teriparatide, Denosumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Sep 17, 2026, 6:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3

NCT00688246
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
biologic sample preservation procedure, dual x-ray absorptometry
Other · Procedure
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
35 Years and older · Female only
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
13
States / cities
Torrance, California • Washington D.C., District of Columbia • Scarborough, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 17, 2026, 6:24 PM EDT
Terminated Phase 4 Interventional Results available

Bone Microarchitecture in Osteopenic Postmenopausal Women

NCT00577395
View directory record Official record
Conditions
Osteoporosis
Interventions
placebo, risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 57 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Tuscon, Arizona • Omaha, Nebraska • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 17, 2026, 6:24 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis

NCT00000430
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
Alendronate, Estrogen/progestin therapy
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
60 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 3, 2007 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

NCT00048074
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
1,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Little Rock, Arkansas • Irvine, California • Rancho Mirage, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 4 Interventional

PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia

NCT02598453
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
60
States / cities
Montgomery, Alabama • Lake Havasu City, Arizona • Paradise Valley, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 17, 2026, 6:24 PM EDT
Not listed Phase 3 Interventional

Comparative Efficacy, Safety, PK, and Immunogenicity Study

NCT05853354
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab
Biological
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Thousand Oaks, California • Hialeah, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 17, 2026, 6:24 PM EDT